Gilead Sciences, Inc.
NEWS
Foster City-based Gilead Sciences says its inhaled version of remdesivir, which has been increasingly used in research and practice to combat COVID-19 in hospitalized patients, won’t be available any time soon as it needs more testing in clinical research.
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
BioSpace highlights a number of the key M&A deals struck over the past 12 months.
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
Gilead Sciences bolstered its capabilities in treating Hepatitis and other liver diseases with the €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, a company focused on developing therapies for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis.
JOBS
IN THE PRESS